Patient characteristics, adherence, and costs of oral anticoagulation therapy in non-valvular atrial fibrillation using the Dubai Real-World Claims Database.
Anticoagulants
NOAC
atrial fibrillation
claims
healthcare resource utilization
real-world study
Journal
Avicenna journal of medicine
ISSN: 2231-0770
Titre abrégé: Avicenna J Med
Pays: Germany
ID NLM: 101584155
Informations de publication
Date de publication:
Historique:
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Non-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) and have better safety profile than vitamin K antagonists (VKAs). However, there is a dearth of quality, real-world, patient data on the use of these drugs to guide healthcare policies in United Arab Emirates (UAE). The aim is to address the knowledge gap in demographic and clinical profiles of NVAF patients on NOACs (apixaban, rivaroxaban, and dabigatran) and warfarin in UAE. This retrospective cohort analysis utilized the Dubai Real-World Claims Database to extract anonymized longitudinal data on NVAF patients with at least one NOAC or warfarin claim between January 2015 and March 2019. Data examined included comorbidities, healthcare resource utilization (HCRU), treatment adherence, and clinical events. From 11,086 NVAF patients in the database, 940 patients on oral anticoagulant treatment were selected with mean age of 58.6 ± 14.7 years and 73.7% men. At baseline, the mean CHA This study provides important comparative insights about comorbidities, adherence, HCRU, and outcome events among NOAC and warfarin users from real-world clinical practice settings.
Sections du résumé
BACKGROUND
BACKGROUND
Non-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) and have better safety profile than vitamin K antagonists (VKAs). However, there is a dearth of quality, real-world, patient data on the use of these drugs to guide healthcare policies in United Arab Emirates (UAE).
AIMS AND OBJECTIVES
OBJECTIVE
The aim is to address the knowledge gap in demographic and clinical profiles of NVAF patients on NOACs (apixaban, rivaroxaban, and dabigatran) and warfarin in UAE.
MATERIALS AND METHODS
METHODS
This retrospective cohort analysis utilized the Dubai Real-World Claims Database to extract anonymized longitudinal data on NVAF patients with at least one NOAC or warfarin claim between January 2015 and March 2019. Data examined included comorbidities, healthcare resource utilization (HCRU), treatment adherence, and clinical events.
RESULTS
RESULTS
From 11,086 NVAF patients in the database, 940 patients on oral anticoagulant treatment were selected with mean age of 58.6 ± 14.7 years and 73.7% men. At baseline, the mean CHA
CONCLUSION
CONCLUSIONS
This study provides important comparative insights about comorbidities, adherence, HCRU, and outcome events among NOAC and warfarin users from real-world clinical practice settings.
Identifiants
pubmed: 33996647
doi: 10.4103/ajm.ajm_228_20
pii: AJM-11-93
pmc: PMC8101642
doi:
Types de publication
Journal Article
Langues
eng
Pagination
93-102Informations de copyright
Copyright: © 2021 Avicenna Journal of Medicine.
Déclaration de conflit d'intérêts
Ahmed Ghorab and Jean Joury are paid employees of Pfizer Gulf, with ownership of stocks in Pfizer Inc. Nancy Awad, Badarinath Chickballapur Ramachandrachar, and Ashok Natarajan are employees of IQVIA who were paid consultants to Pfizer in connection with the development of this manuscript. Mohamed Farghaly and Moutaz El Kadri have no conflicts to declare.
Références
Arch Fam Med. 1995 Dec;4(12):1017-26
pubmed: 7496550
World Health Stat Q. 1988;41(1):32-6
pubmed: 3376487
Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):477-82
pubmed: 21772004
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Fam Med. 2007 Feb;39(2):132-7
pubmed: 17273956
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
PLoS One. 2017 Oct 10;12(10):e0185642
pubmed: 29016695
Korean J Intern Med. 2020 Jan;35(1):99-108
pubmed: 31014064
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
Stroke. 2017 Aug;48(8):2142-2149
pubmed: 28655814
J Am Coll Cardiol. 2018 Jul 10;72(2):141-153
pubmed: 29976287
Mayo Clin Proc. 2019 Dec;94(12):2427-2436
pubmed: 31668449
Eur J Heart Fail. 2014 Apr;16(4):454-60
pubmed: 24464827
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
BMJ Open. 2018 Dec 19;8(12):e025102
pubmed: 30573490
J Am Coll Cardiol. 2020 Aug 4;76(5):594-622
pubmed: 32680646
Am J Manag Care. 2005 Jul;11(7):449-57
pubmed: 16044982
Arch Intern Med. 2012 Apr 23;172(8):623-31; discussion 631-3
pubmed: 22450212
BMJ Open. 2019 Sep 20;9(9):e031341
pubmed: 31542760
Circulation. 1981 Oct;64(4):669-73
pubmed: 7023743
Heart. 2015 Nov;101(21):1748-54
pubmed: 26307057
Pharmacoepidemiol Drug Saf. 2006 Aug;15(8):546-54
pubmed: 16586470
J Korean Med Sci. 2018 Jun 26;33(34):e213
pubmed: 30127705
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
Value Health. 2008 Jan-Feb;11(1):44-7
pubmed: 18237359
J Am Coll Cardiol. 2014 May 27;63(20):2141-2147
pubmed: 24657685
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):171-180
pubmed: 31119266
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
J Am Coll Radiol. 2008 Apr;5(4):555-60
pubmed: 18359442
JAMA. 2001 Jun 13;285(22):2864-70
pubmed: 11401607